Skip to main content
. 2020 Dec 8;3(2):69–82. doi: 10.1096/fba.2020-00092

Figure 3.

Figure 3

Correlation between SIGLEC12 genomic status and frequency or progression, only of late‐stage cancers. A, Prostate cancer patients diagnosed with PSA test followed up after 5 years. (NED‐No evidence of disease: n = 84, BCR‐ Biochemical Cancer Recurrence: n = 28 and Met‐Metastasis: n = 10). B, Seventh‐Day Adventist population where environmental risk factors for cancer are minimal. The percentage of patients with cancer and without cancer is shown to be either SIGLEC12‐/‐ (non‐expresser, n for cancer = 14, n for non‐cancer = 20) or SIGLEC12+/‐ and SIGLEC12+/+ (expresser, n for cancer = 40 and n for non‐cancer = 33). C and D, Percentage of patients who are Siglec‐XII expressers (SIGLEC12+/‐ and SIGLEC12+/+) or non‐expressers (SIGLEC12‐/‐) in the FIRE3 and TRIBE stage IV colorectal cancer cohorts (FIRE3 cohort: expresser n = 85, non‐expresser n = 16 and TRIBE cohort: expresser n = 177, non‐expresser n = 27). E and F, Overall survival of colorectal cancer patients that are Siglec‐XII expressers versus non‐expressers (*p value <0.05)